Confo Therapeutics Secures VLAIO Grant Supporting Drug Discovery & Development in Endocrine and Metabolic Diseases
March 28 2024 - 6:00AM
Business Wire
Confo Therapeutics, a leader in the discovery of novel medicines
targeting G-protein coupled receptors (GPCRs), announced today that
it has been awarded a EUR 1.6 million grant from Flanders
Innovation & Entrepreneurship (VLAIO). The 2-year grant will be
used to expand Confo’s ongoing R&D efforts in the discovery of
next-generation medicines targeting Class B GPCRs using its
patent-protected technology platform. Class B GPCRs are recognized
as important targets for new medicines, particularly in chronic
endocrine and metabolic diseases.
Cedric Ververken, CEO of Confo Therapeutics, commented:
“Receiving this additional VLAIO grant will strengthen our existing
small molecule and antibody discovery efforts on high-value Class B
GPCRs, which further paves the way to unlock new treatments for a
range of endocrine and metabolic indications including obesity. We
are grateful to VLAIO for its continued support, which will bolster
our capabilities in Class B GPCR drug discovery and
development.”
Christel Menet, CSO of Confo Therapeutics, added: “Despite
advances made with peptide-based treatments, the need for improved
molecules capable of targeting Class B GPCRs for the treatment of
endocrine and metabolic diseases remains high. Our platform has
already been proven on various targets including orphan GPCRs and
Class B GPCRs, and with VLAIO’s support we will be able to
accelerate our efforts to further unlock valuable targets in
obesity and related metabolic indications.”
Confo’s proprietary platform, which includes our ConfoBody® and
ConfoChimer® technologies, enables successful discovery of
molecules targeting challenging GPCRs. ConfoBodies® are novel VHH
domains which stabilize GPCRs in pharmacological states of interest
by binding to their intracellular surface. ConfoChimer® technology
enables universal ConfoBodies® to be used across the GPCR
superfamily which expedites the discovery process. Confo has an
extensive worldwide patent estate covering this suite of
technologies.
About Confo Therapeutics
Confo Therapeutics is the only GPCR company with a proprietary
discovery engine that precisely targets desired GPCR conformations.
This unique capability allows us to unlock a vast untapped
potential for the discovery and development of breakthrough
medicines. We are a clinical-stage company advancing a robust
pipeline of large and small molecules focused on validated targets
in endocrine and metabolic diseases, as well as addressing a
broader array of critical unmet medical needs in collaboration with
our partners. Our team of accomplished experts is dedicated to
advancing our patent-protected technology, expanding our
capabilities, and building out our pipeline to achieve the best
possible therapeutic outcomes for patients. For more information,
visit www.confotherapeutics.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240328537717/en/
Confo Therapeutics Dr. Cedric Ververken, CEO +32 (0) 9
396 74 00 Email: info@confotherapeutics.com
Trophic Communications Desmond James or Valeria Fisher
+49 (0) 1516 7859086 or +49 (0) 175 8041816 Email:
confo@trophic.eu